Novo Nordisk's pricing approaches within the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of value gouging, stating the stark distinction amongst U.S. rates and people in Europe and copyright. are scheduled to obtain operation or ot